AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

AMGEN INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$424.94−7.55 (-1.75%)

Close on Oct 19, 2026

Market cap: $231.17B
P/E (TTM): 26.4
Dividend yield: 2.27%

Fundamental chart

Pick a measure to chart its full history

$36.75BFY2025, +6.3% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Amgen's annual and quarterly filings with the SEC
Per-share figures adjusted for the 2-for-1 split on Nov 22, 1999
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AMGN.

Revenue growth9.1% · median 3.1%

Gross margin69.5% · median 73.6%

Operating margin30.0% · median 8.3%

Net margin23.0% · median 8.3%

Company	Revenue	Growth
PFE	$63.70B	-0.2%
BMY	$49.19B	+3.1%
AMGN	$38.10B	+9.1%
GILD	$30.46B	+5.5%
REGN	$15.53B	+9.3%
BIIB	$10.03B	+0.3%

Company

Next earnings (est.): Nov 3, 2026, during market hours
Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 31,500
Held by institutions: 82.7%
Auditor: Ernst & Young LLP
SEC CIK: 318154

Advertisement
300 × 250